Claude Perreault

This inventor holds 8 USPTO granted patents and 7 published patent applications and 2 EPO patents. Top assignees: Universitéde Montreal, Rsem, Limited Partnership, Biosystemix Ltd.. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Claude Perreault. Retrieved from https://idiyas.com/inventor/claude-perreault

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 7)

% Patents Active = 37.5

EPO Patents = 2 (Patent Applications = 11)

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 2(Granted Patents)

Location History:

Outremont, CA (2015 - 2019)
Québec, CA (2019)
Montreal, CA (2010 - 2023)

Company Filing History:

7 out of 189

Universitéde Montreal

patents

2 out of 14

Rsem, Limited Partnership

Valorisation-Recherche, Limited Partnership

patents

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12721812 - Method for stimulating T cell response against lymphoblastic leukemia with leukemia tumor specific antigens (2026-09-01),

2. 12692289 - TUMOR-SPECIFIC PEPTIDE ANTIGENS FOR OVARIAN CANCER AND USES THEREOF (2026-07-28),

3. 11702450 - Proteogenomic-based method for identifying tumor-specific antigens (2023-07-18),

4. 10414813 - Minor histocompatibility antigens and uses thereof (2019-09-17),

5. 10239917 - Method for identifying novel minor histocompatibility antigens (2019-03-26),

6. 9500651 - Method for identifying novel minor histocompatibility antigens (2016-11-22),

7. 9102981 - Assessment and reduction of risk of graft-versus-host disease (2015-08-11),

8. 7763425 - Assessment and reduction of risk of graft-versus-host disease (2010-07-27),

Title: Claude Perreault: Innovator in Cancer Immunotherapy

Introduction

Claude Perreault is a distinguished inventor based in Outremont, Canada. He has made significant contributions to the field of cancer immunotherapy, holding a total of six patents. His work focuses on identifying tumor-specific antigens, which play a crucial role in the immune response against cancer.

Latest Patents

One of his latest patents is a proteogenomic-based method for identifying tumor-specific antigens. This method utilizes RNA-sequencing data from cancer and normal-matched samples to identify non-tolerogenic tumor-specific antigens. These antigens are derived from various genomic regions and are essential for the recognition of tumor cells by CD8 T cells. Another notable patent involves novel minor histocompatibility antigens (MiHAs), which are selected based on their minor allele frequency and tissue distribution. These MiHAs have potential applications in cancer immunotherapy, particularly for treating hematologic cancers such as leukemia.

Career Highlights

Claude Perreault has worked with prominent institutions, including the Université de Montréal and Rsem, Limited Partnership. His research has significantly advanced the understanding of tumor immunology and the development of targeted therapies.

Collaborations

Throughout his career, Perreault has collaborated with notable colleagues, including Pierre Thibault and Sébastien Lemieux. These partnerships have fostered innovation and contributed to the success of his research endeavors.

Conclusion

Claude Perreault's innovative work in cancer immunotherapy exemplifies the impact of scientific research on medical advancements. His patents and collaborations continue to pave the way for new therapeutic strategies in the fight against cancer.

Profile summary based on public USPTO records.